All News

Top news of the week from Specialty Pharmacy Times.

All 50 states accept the ExCPT exam from National Healthcareer Association (NHA), helping more pharmacy technicians earn a national credential.

Researchers have found that patients with high blood pressure (BP) who take all their antihypertensive medications at bedtime have better controlled blood pressure and a significantly lower risk of death or illness caused by heart or blood vessel problems, compared to patients who take their medications in the morning.1

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

Ron Lanton III, Esq., discusses challenges in launching biosimilars after they've been approved.

Psoriasis may increase the risk of cancer incidence and cancer-related mortality in affected individuals.

Effective December 31, 2019, Amgen’s 60% annual list price cut for evolocumab (Repatha) will be fully implemented.

Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).

Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.

The influenza A virus remains contagious in wet mucus from infected patients, even after being exposed to an ethanol-based disinfectant.

McKesson’s Health Mart has announced a partnership with Amazon Hub Counter pickup points, offering customers more convenient delivery options.

Top news of the day from across the health care landscape.

Patients with metastatic breast cancer who receive care aligned with National Comprehensive Cancer Network guidelines experienced less financial burden than patients who received guideline-discordant treatment.

According to the 2018 National Survey on Drug Use and Health, 9.9 million Americans misused controlled prescription drugs. On October 26, 2019 health care organizations across the country are participating in National Prescription Drug Take Back Day to help address this public safety and public health issue.

Niraparib (Zejula) received approval for patients with advanced homologous recombination deficiency-positive status ovarian cancer who have received 3 or more prior chemotherapies.

Results from the safety and efficacy trial of revefenacin (REV) demonstrated that the drug had a safety profile similar to foremoterol (FOR). In addition, patients with COPD in the suboptimal peak inspiratory flow rate trial (sPIFR) showed lower weight, BMI, and lung function in comparison to patients with optimal peak inspiratory flow rate (oPIFR) in a second study.

Bemcentinib is being evaluated as a treatment for elderly patients with acute myeloid leukemia whose disease has relapsed.

Top news of the day from across the health care landscape.

In addition to Jennifer Garner, actresses Julia Louis-Dreyfus and Christina Applegate are advocates for breast cancer, both being survivors of the disease.

Starting on October 21st, aclidinium bromide and formoterol fumarate (DUAKLIR PRESSAIR, Circassia) will be available for the maintenance treatment of patients with COPD.

The American Society of Health-System Pharmacists (ASHP) has awarded Scott J. Knoer, Pharm.D., M.S., FASHP, with its John W. Webb Lecture Award.

The high cost of treating blood cancer may contribute to delayed initiation of active treatment in newly-diagnosed Medicare beneficiaries.

Researchers note that a metabolic imbalance in some patients with cancer following treatment with nivolumab is associated with shorter survival.

Officials from the FDA have expanded the label of insulin aspart injection pumps, 100 u/mL (Fiasp, Novo Nordisk) to include use in insulin infusion pumps.

One in 8 pharmacies closed from 2009 to 2015, despite an overall increase in the number of pharmacies during this time.

Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.

The new, standardized, ready-to-use formulation of phenylephrine HCl can help reduce medication errors and improve patient safety.